1117 results about "Substituent" patented technology

Monoorgano tin trialkoxide compounds having chemical formula R'SnX3 and containing less than about 5 mol% R'2SnX2are described. R' is an optionally substituted organic substituent having about 1 to about 20 carbon atoms and each X is independently ORf, wherein Rf is a fluorinated organic substituent having about 1 to about 20 carbon atoms. Methods for synthesizing and purifying these compounds are also provided. The monoorgano tin compounds may be used for the formation of high-resolution EUV lithography patterning precursors and are attractive due to their high purity and minimal concentration of diorgano tin impurities.

A compound of Formula Ir(LA)x(LB)y(LC)z is provided where x and y are independently 1 or 2; z is 0 or 1; and x+y+z=3; first ligand LA includes a structure of Formula I,ligand LB includes a structure of Formula II:and ligand LC is a bidentate ligand. In the compounds, moiety B is a polycyclic fused ring system comprising at least four rings; each of moiety C and moiety D is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 to Z6 is C or N; L0 is a direct bond or a linking group; YA is a linking group; each substituent is hydrogen or a General Substituent defined herein; and any two substituents may be joined or fused to form a ring. Formulations, OLEDs, and consumer products containing the compound are also provided.

This polarizing film containing a base material is characterized in that the base material includes an azo compound represented by formula (1) or a salt thereof (compound A), and an azo compound represented by formula (2) or a salt thereof (compound B). (In formula (1), X1 represents an amino group which may have a substituent, a phenylamino group which may have a substituent, a naphthylamino group which may have a substituent, a benzoylamino group which may have a substituent, or a naphthotriazole group which may have a substituent, Q1 and R1 to R4 each independently represent an optional substituent, and m represents an integer of 1 to 3.) (In formula (2), X2 represents an amino group which may have a substituent, a phenylamino group which may have a substituent, a naphthylamino group which may have a substituent, a benzoylamino group which may have a substituent, or a naphthotriazole group which may have a substituent, Q2 and R5 to R8 each independently represent an optional substituent, R9 represents a hydrogen atom or a methyl group, and n represents an integer of 1 to 3.)

The invention relates to organic electroluminescent materials and devices. There is provided a compound having the formula Ir (LA) x (LB) y (LC) z wherein x and y are each independently 1 or 2, z is 0 or 1, and x + y + z = 3; the first ligand LA comprises a structure as shown in a formula I; lB comprises a structure of formula II; and LC is a bidentate ligand. In these structures, each of the moieties A, C and D is a monocyclic or polycyclic fused ring system; each of X1-X7 and Z1-Z4 is C or N; y1 is a linking group; z is Si or Ge; and each substituent is hydrogen or a universal substituent as defined herein. Formulations, OLEDs, and consumer products containing the compounds are also provided. Further provided is a method of preparing a compound of formula M '(LA') p (LB ') q (LC') r as defined herein.

An organometallic complex is represented by general formula (1).M is Pd or Pt. B-A-B is a tetradentate ligand formed by bonding a ring A to rings B. The ring A is a hydrocarbon aromatic ring or heteroaromatic ring that may have a substituent, and is selected from a benzene ring, etc. The substituent that the ring A may have is selected from a linear or branched C1 to C6 alkyl group, etc. Each of the rings B is a monocyclic heteroaromatic ring that may have a substituent, and is selected from a pyridine ring, etc. The substituent that the ring B may have is selected from a linear or branched C1 to C6 alkyl group, etc. Each X-Y is a bidentate ligand, and atoms bonded to M are selected from C, N, and O atoms. The two bidentate ligands do not bond together.

The invention relates to organic electroluminescent materials and devices. The present invention provides a compound of formula Ir (LA) x (LB) y (LC) z, wherein LA has a structure comprising formula I # imgabs0 #. In Formula I, each of X3 to X7 is N or CR; z is an electron withdrawing group; y is a linking group; each R, R ', R3, R4, R5, RA and RB is hydrogen or a universal substituent as defined herein; and each R1 and R2 is a substituent comprising at least one carbon atom. The invention also provides formulations, OLEDs and consumer products containing the compounds.

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The invention belongs to the technical field of organic electroluminescence, and particularly provides an electroluminescent material and an organic electroluminescent device comprising the same, the electroluminescent material comprises a combination of a first organic compound and a second organic compound, the first organic compound has a structure as shown in a formula I, and the second organic compound has a structure as shown in a formula II; the second organic compound has a structure as shown in a formula II; through structural design of the first organic compound and the second organic compound, particularly introduction of a substituent group at a specific site, and synergistic compounding of the two organic compounds, the material has higher glass transition temperature Tg and excellent thermal stability while having excellent photoelectric properties and carrier transport properties. The electroluminescent material is used for the organic electroluminescent device, is especially suitable for a luminescent layer, and can effectively ensure the uniformity of a deposited film, so that the thermal stability of the device is excellent, and the high-temperature test life is remarkably prolonged.

Synthesis reactions are described to efficiently and specifically form compounds of the structure RSnL3, where R is an organic ligand to the tin, and L is hydrolysable ligand or a hydrolysis product thereof. The synthesis is effective for a broad range of R ligands. The synthesis is based on the use of alkali metal ions and optionally alkaline earth (pseudo-alkaline earth) metal ions. Compounds are formed of the structures represented by the formulas RSn(C≡CSiR′3)3, R′R″ACSnL3, where A is a halogen atom (F, Cl, Br or I) or an aromatic ring with at least one halogen substituent, R′R″(R″′O)CSnL3 or R′R″(N≡C)CSnZ3.

Provided is a resin comprising a polycarbonate structural unit represented by formula (UN1) and a terminal structure having a vinyl group (with the proviso that any polycarbonate structural unit represented by formula (A1) and any terminal structure represented by formula (A2) are excluded). [In formula (UN1), Ux is a single bond or a divalent group, R1 and R2 are each independently a substituent, n is 0, 1, 2, 3, or 4, m is 0, 1, 2, 3, or 4, and * indicates a linking bond. Symbol * in formula (A1) indicates a linking bond and symbol * in formula (A2) indicates a linking bond to the repeating unit located at an end of the resin.]

To provide a photosensitive composition capable of further improving diffraction characteristics.The present technology provides a photosensitive composition including: at least a compound represented by the following general formula (1); a binder resin; and a photoinitiator.In the general formula (1), X1 represents an oxygen atom, a nitrogen atom, a phosphorus atom, a caron atom, or a silicon atom.Y1 and Y2 each represent a benzene ring or a naphthalene ring, and both Y1 and Y2 do not represent benzene rings.R1 to R3 each represent a hydrogen or a substituent group represented by *—Z1(R4)d (* represents a bonding site).Z1 represents a single bond, a saturated hydrocarbon group having a valence of 2 or higher, or an unsaturated hydrocarbon group having a valence of 2 or higher, and the saturated hydrocarbon group or the unsaturated hydrocarbon group may have an ether bond and / or a thioether bond.R4 represents a hydrogen or a polymerizable substituent group.

A compound having a first ligand LA comprising a structure of Formula I,is provided. In Formula I, moiety B is a monocyclic ring or a polycyclic fused ring system; each of X1 to X6 is C or N; Y is a linking group; K is a direct bond or a linking group; each substituent is hydrogen or a General Substituent defined herein; and at least one of the following conditions is true: (1) an RA substituent is joined with an RB substituent to form a ring AB, which may be substituted by one or more RAB substituents; or (2) X5 and X6 are C, and the corresponding two RA substituents are joined to form a cyclic moiety A1, which may be substituted by one or more RA1 substituents; and moiety B is a polycyclic fused ring system. Formulations, OLEDs, and consumer products containing the compound are also provided.

An organic light emitting device having improved driving voltage, efficiency and lifetime, the device comprising a light emitting layer including one or more compounds of Chemical Formula 1, one or more compounds of Chemical Formula 2, and one or more compounds of Chemical Formula 3:wherein: X′1 is N and X′2 is O, or X′1 is O, and X′2 is N; X″ is O or S; one of R′1 to R′7 is linked with Chemical Formula 2A:one of R″1 to R″10 is linked with Chemical formula 3A, and the rest are hydrogen or deuterium:Ar1, Ar2, Ar′1, Ar′2, Ar″1, Ar″2 are each independently a substituted or unsubstituted C6-60 aryl or C2-60 heteroaryl containing one or more of N, O and S; and the other substituents are as defined in the specification.

A compound having a ligand LA of Formula I,is disclosed. In Formula I, ring B is a 5-membered or 6-membered ring; K is a direct bond, O, or S; X is O, S, Se, NR, CRR′, SiRR′, or GeRR′; R1 and R2 are each independently selected from a variety of substituents; each R, R′, RA, and RB is independently hydrogen or a substituent; LA is coordinated to a metal M selected from Os, Ir, Pd, Pt, Cu, Ag, or Au by the dashed lines; any two adjacent of R1, R2, R, R′, RA, or RB can be joined or fused to form a ring, with the proviso that when ring B is a 6-membered ring, two RB substituents are not joined to form a fused 6-membered aromatic ring. Organic light emitting devices, consumer products, formulations, and chemical structures containing the compounds are also disclosed.

Provided in the present invention are a monosubstituted cyclic ligand, and a preparation method therefor and a use thereof, and a monosubstituted cyclic rare earth complex, and a preparation method therefor and a use thereof, relating to the technical field of contrast agents. The monosubstituted cyclic ligand uses the ring structure of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid as a parent ring, and an R-modified tyrosine group increases the structural rigidity of the parent ring and improves the stability of the complex. Direct introduction of benzyloxy-, ethoxy- or hydroxy-substituted benzyl substituents on the carbon atoms of the DOTA ring maintains the original eight-coordination structure, and improves the relaxation rate of the complex, in addition to increasing the stability of the complex. Compared with Gd-DOTA, both the kinetic inertia and the relaxation rate are improved. The complex formed by the ligand and Gd(III) or Eu(III) is highly stable, and has strong specificity for the liver or for inflammation, and causes no obvious damage to the heart, the liver, the spleen, the lungs or the kidneys.

Compound of Formula I,is provided. In Formula I, rings A, B, C, and D are 5- or 6-membered rings; each of X1-X5, X21-X22, and Z1-Z3 is C or N; each of L1, L2, and L3 is selected from a direct bond or a divalent linker; each of a and b is 0 or 1; Y is O, S, Se, or NRY; W is O, S, NRW, C═RW, or CRWRW′; up to 1 of Z1 to Z3 is N; each R, R′, RA, RB, RC, RD, RY, RW, and RW′ is hydrogen or a substituent. Formulations, OLEDs, and consumer products containing the same are also disclosed.

To provide a compound useful as a material for an organic device such as an organic electroluminescent element.SOLUTION: Polycyclic aromatic compounds having a structure consisting of one or two or more structural unit (s) represented by the formula (1); (Ra1 to Ra3, Rb1 to Rb4, Rc1 to Rc4 are independently H or substituents; provided that at least one of Rc1 to Rc4 is a group represented by the formula (1-1); Y1 is B; and are independently> N-RNX; RNX is substituted / unsubstituted aryl; at least one of the aryl ring and the heteroaryl ring in the above structure may be fused with at least one cycloalkane, and H in the above structure may be replaced by D. X1 X2. ) SELECTED DRAWING: None

When a compound represented by the following general formula is used, an organic light-emitting device having excellent characteristics can be provided. One or more of R1 to R5 represent a cyano group, and two or more represent a donor group; X1 to X3 represent N or C(R); R represents H, D, or a substituent; one or more of Ar1 and Ar2 represent a group bonding via a benzene ring that has a donor group bonding via a nitrogen atom; and L1 represents a single bond or a linking group.

The present invention relates to pyrazole derivatives of formula (X)wherein ring A is a pyrazole and substituents RB1, RB2, n, RQ1, RQ2, RQ3, and RQ4 are as defined in claim 1, their manufacture, and their use in the manufacture of agrochemicals and pharmaceuticals.

A compound is disclosed that has a metal coordination complex structure having at least two ligands coordinated to the metal; wherein the compound has a first substituent R1 at one of the ligands' periphery; wherein a first distance is defined as the distance between the metal and one of the atoms in R1 where that atom is the farthest away from the metal among the atoms in R1; wherein the first distance is also longer than any other atom-to-metal distance between the metal and any other atoms in the compound; and wherein when a sphere having a radius r is defined whose center is at the metal and the radius r is the smallest radius that will allow the sphere to enclose all atoms in the compound that are not part of R1, the first distance is longer than the radius r by at least 2.9 A.

Provided is a compound including a first ligand LA of Formula IIn Formula I, ring C is a 5- or 6-membered ring; each of X1 to X8 is C or N; one of X1 to X4 is C and is connected to ring C, and one of X1 to X4 is N and is coordinated to a metal M; Y is a divalent linker; K is a direct bond, O, or S; each R′, R″, RA, RB, and RC is hydrogen or a general substituent; at least one of RA or RB comprises an electron-withdrawing group; at least one of RB is a cyclic group; and metal M is selected from Os, Ir, Pd, Pt, Cu, Ag, and Au. Formulations, devices, and consumer products comprising the compound are also disclosed.

The invention relates to organic electroluminescent materials and devices. There is provided a compound having a first ligand LA having a structure of Formula I wherein consecutive two of X1 to X8 are C and bonded to the structure of Formula II in Formula I, Part A is a monocyclic or polycyclic fused ring system; each of Z1 to Z2 and X1 to X12 is C or N; each of Y1 and Y2 is a linking group; k is a direct bond or a linking group; each substituent is hydrogen or a universal substituent as defined herein; and LA is coordinated with the metal M. Also provided is a compound having the formula Ir (LA *) x (LB *) y (LC *) z as defined herein. Formulations, OLEDs and consumer products containing these compounds are further provided.

Provided is a low-molecular compound or a salt thereof, or a solvate thereof which has the ability to activate Nrf2.The present invention provides a compound represented by the formula (1) or a salt thereof, or a solvate thereof, wherein Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2 and Ra3 are each independently selected from the group consisting of hydrogen, halogen and C1-C6 alkoxy, Xb1, Xb2 and Xb3 are each independently selected from the group consisting of CH2, O, NH, S and C═O, Y is C6-C10 aryl optionally having a substituent or 5- to 10-membered heteroaryl optionally having a substituent, and Z is C6-C10 aryl optionally having a substituent, 5- to 10-membered heteroaryl optionally having a substituent or C1-C6 alkyl optionally having a substituent.

To provide a superior agricultural and horticultural plant disease control agent.SOLUTION: The present invention provides an aryl oxadiazole compound represented by general formula [I] or a salt thereof, and an agricultural and horticultural plant disease control agent comprising the same as an active ingredient [where A1, A2, A3, and A4 each independently represent a nitrogen atom, CH, or C-R4; Y represents an oxygen atom or a sulfur atom; X represents a halogen atom; Z represents a C1-C6 alkyl group, a C1-C6 alkoxy group, or the like; R1 and R2 represent a hydrogen atom, a C1-C6 alkyl group, or the like; and R3 represents a C1-C6 alkyloxycarbonyl group, a phenyl group (the group being substituted with one or more substituents selected from R5 substituents), a C10-C12 aryl group (the group optionally being substituted with one or more substituents selected from R5 substituents), or a 5-12-membered heteroaryl group (the group optionally being substituted with one or more substituents selected from R5 substituents)].SELECTED DRAWING: None

This invention relates to the use of compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, in the treatment or prevention of mycobacterial infections, wherein: one of R2 and R3 is H, and the other is (CR) a R b ) n Y; Y is selected from CO2R c CN and CONR e R f R4 is selected from H, halogens, CN, alkyl and alkoxy groups; R6 is selected from H, F, Br, I, COOH, CN, COR. d CO2R d Alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, OH, SR d SOR d SO2R d SO2NR d R d NHSO2R d aryl and heteroaryl groups, wherein the aryl or heteroaryl group is optionally substituted by one or more substituents selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkoxy groups; R7 is selected from H, halogen, alkyl, and alkoxy groups; R9 is selected from H, COR... d Alkyl, haloalkyl, aryl, CO-aryl, CO-haloaryl, aralkyl and haloaralkyl; R1, R5 and R8 are H; each R a R b R c R d R e and R f The compounds are independently selected from H, alkyl, and haloalkyl groups; n is 1 to 6. Other aspects of the invention relate to subgroups of compounds of formula (Ia), pharmaceutical compositions comprising such subgroups, and their use in the treatment or prevention of mycobacterial infections.

The invention provides a synthesis method of a thioether ligand and a palladium-catalyzed 2-aryl indole compound, and designs an application of the biphenyl thioether ligand and a palladium catalyst in preparation of the 2-aryl indole compound. Indole and arylboronic acid are subjected to a reaction under the action of a palladium catalyst and a biphenyl sulfide ligand, and the structural formula of the biphenyl sulfide ligand is shown in the specification. Ar is phenyl, furyl, thienyl, naphthyl or phenyl substituted by one or more substituent groups; r1 is methyl, methoxyl, fluorine atom, chlorine atom, bromine atom or methyl ester group; r2 is the same or different and is methyl, ethyl, isopropyl, isobutyl, cyclohexyl, benzyl, n-butyl or n-hexyl; r3 is alkoxy, alkylthio, substituted amino or halogen; the palladium catalyst is a divalent palladium compound.

An object of the present invention is to provide a chemical liquid which makes it possible to form a thinner resist film having a uniform thickness on a substrate by using a small amount of resist composition and demonstrates excellent defect inhibition performance. Another object of the present invention is to provide a pattern forming method. A chemical liquid of the present invention contains a mixture of two or more kinds of organic solvents, in which the organic solvents are selected from the group consisting of compounds represented by Formulae (1) to (7), compounds represented by Formulae (9) to (11), a 3- to 5-membered cyclic ketone compound that may have a substituent, a cyclic ketone compound with 6 or more members that may have a substituent, a lactone compound, and a lactam compound, the chemical liquid contains or does not contain an ether-based compound other than the compounds represented by Formula (1), Formula (5), Formula (7), and Formulae (9) to (11), and in a case where the chemical liquid contains the ether-based compound, a content of the ether-based compound in the chemical liquid is less than 10 mass ppm with respect to a total mass of the chemical liquid.

A composition includes at least one of: (a) an amino acid isocyanate adduct of Formula I:and salts thereof, and (b) an amino acid epoxide adduct of Formula II:and salts thereof. R1 is a moiety of a monomer or prepolymer including two —NCO functional groups, which have reacted to form urea linkages; R2 is a moiety of a monomer or prepolymer including two glycidyl ether epoxide functional groups, which have reacted to form amino alcohol groups; R6, R7, R20 and R21 are independently (CH2)n, n is 1-6; R8, R9, R10 and R11 are independently hydrogen or CH2X; R12, R13, R14 and R15 are independently hydrogen, alkali metal cation, or X; R16 and R17 are independently hydrogen or X; R18 and R19 are independently hydrogen, SiO3 or X; and each X is independently hydrogen or a substituent. Controlled release particles, consumer products and methods including the composition are also disclosed.

A compound having a structure represented by general formula (1). In general formula (1), R101 to R121 are each independently a hydrogen atom or a substituent, where R101 to R121 are not a substituted or unsubstituted N-carbazolyl group. The structure represented by general formula (1) has at least one group represented by general formula (2). In general formula (2), at least one of X1-X5 is represented by a nitrogen atom.

A 1,10-phenanthroline derivative or a 2,2′-bipyridine derivative having different substituents at symmetrical positions is provided. An organic compound represented by General Formula (G1) or General Formula (G2) below is provided. In General Formula (G1) or (G2) below, any one of X2 to X5 or any one of X6 to X9 represents a halogen or a trifluoromethanesulfonyl group, and the others represent hydrogens. Any one of R2 to R5 or any one of R6 to R9 represents an aliphatic cyclic amino group. Note that a carbon to which the halogen or the trifluoromethanesulfonyl group is bonded and a carbon to which the aliphatic cyclic amino group is bonded are at line-symmetrical positions in a main skeleton (a 1,10-phenanthroline skeleton or a 2,2′-bipyridine skeleton).